Baidu
map

CANCER CELL:MLL2,而不不是MLL1,在维持MLL重排的急性骨髓性白血病中起主要作用

2017-06-13 MedSci MedSci原创

人类混合型白血病(MLL,MLL1,KMT2A)基因在急性淋巴细胞白血病和急性骨髓性白血病(AML)中被染色体易位和其他重排所破坏,并且在婴儿中发生频率高,而在儿童和成人中频率低。MLL1组蛋白甲基转移酶基因经历许多不同的染色体重排以产生预后不良的白血病。

人类混合型白血病(MLL,MLL1,KMT2A)基因在急性淋巴细胞白血病和急性骨髓性白血病(AML)中被染色体易位和其他重排所破坏,并且在婴儿中发生频率高,而在儿童和成人中频率低。MLL1组蛋白甲基转移酶基因经历许多不同的染色体重排以产生预后不良的白血病。存在的野生型等位基因是最常见的,但不总是保留。 野生型等位基因在多大程度上有助于白血病发生是不清楚的。在这项研究中,我们利用严格的独立动物模型证明,内源性MLL1对于MLL重新排列型白血病是不必要的。通过共同敲除最接近的旁系同义基因Mll2解决了潜在的冗余问题。令人惊讶的是,单独的Mll2缺失对MLL-AF9转化细胞的存活有显着的影响,并且额外的Mll1缺失进一步降低了生存力和增殖。我们表明,MLL1 / MLL2协作不是通过冗余作用,而是调节不同的途径。这些发现突出了MLL2作为MLL重排白血病药物靶标的相关性,并表明其在AML中具有更广泛的意义。

意义:破坏MLL1基因的染色体易位产生导致儿童期和成人白血病预后不良的致癌基因。尽管进行了广泛的研究,靶向MLL融合蛋白(MLL-FP)的有效策略尚未达到临床实践。在这里,我们讨论了非重排的MLL1等位基因是否在MLL重排的白血病中发挥作用,从而成为合理的治疗靶点。我们发现内源性Mll1的缺失对MLL-FP驱动的白血病发生没有影响。然而,我们发现其最接近的旁系同源基因Mll2具有意想不到的作用。Mll2缺失减少了MLL-AF9白血病的存活,并且在这种情况下Mll1缺失加剧了这种作用。这些数据支持以MLL2本身为目标的治疗策略。

原文出处:

Yufei Chen,Tobias Neff,Yoo Lee ,et al.MLL2, Not MLL1, Plays a Major Role in Sustaining MLL-Rearranged Acute Myeloid Leukemia.[J].Cancer Cell 31, 755–770 June 12, 2017;DOI:http://dx.doi.org/10.1016/j.ccell.2017.05.002


版权声明:本文系梅斯MedSci原创编译整理,未经本网站授权不得转载和使用。如需获取授权,请点击

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2057544, encodeId=5f2e205e544d4, content=<a href='/topic/show?id=b2a812004a8' target=_blank style='color:#2F92EE;'>#MLL1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12004, encryptionId=b2a812004a8, topicName=MLL1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Fri Jun 30 10:44:00 CST 2017, time=2017-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780720, encodeId=a43b1e8072072, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Thu Jun 15 05:44:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870001, encodeId=4fe218e000143, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Apr 19 19:44:00 CST 2018, time=2018-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960260, encodeId=23dc196026064, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Sep 02 02:44:00 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424102, encodeId=96201424102dd, content=<a href='/topic/show?id=4ece524e593' target=_blank style='color:#2F92EE;'>#急性骨髓性白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52475, encryptionId=4ece524e593, topicName=急性骨髓性白血病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07ce3903085, createdName=zxxiang, createdTime=Thu Jun 15 14:44:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514409, encodeId=f21d15144090e, content=<a href='/topic/show?id=1ae010211143' target=_blank style='color:#2F92EE;'>#髓性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102111, encryptionId=1ae010211143, topicName=髓性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae8810654266, createdName=more is better!, createdTime=Thu Jun 15 14:44:00 CST 2017, time=2017-06-15, status=1, ipAttribution=)]
    2017-06-30 chenhongpeng
  2. [GetPortalCommentsPageByObjectIdResponse(id=2057544, encodeId=5f2e205e544d4, content=<a href='/topic/show?id=b2a812004a8' target=_blank style='color:#2F92EE;'>#MLL1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12004, encryptionId=b2a812004a8, topicName=MLL1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Fri Jun 30 10:44:00 CST 2017, time=2017-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780720, encodeId=a43b1e8072072, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Thu Jun 15 05:44:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870001, encodeId=4fe218e000143, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Apr 19 19:44:00 CST 2018, time=2018-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960260, encodeId=23dc196026064, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Sep 02 02:44:00 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424102, encodeId=96201424102dd, content=<a href='/topic/show?id=4ece524e593' target=_blank style='color:#2F92EE;'>#急性骨髓性白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52475, encryptionId=4ece524e593, topicName=急性骨髓性白血病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07ce3903085, createdName=zxxiang, createdTime=Thu Jun 15 14:44:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514409, encodeId=f21d15144090e, content=<a href='/topic/show?id=1ae010211143' target=_blank style='color:#2F92EE;'>#髓性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102111, encryptionId=1ae010211143, topicName=髓性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae8810654266, createdName=more is better!, createdTime=Thu Jun 15 14:44:00 CST 2017, time=2017-06-15, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2057544, encodeId=5f2e205e544d4, content=<a href='/topic/show?id=b2a812004a8' target=_blank style='color:#2F92EE;'>#MLL1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12004, encryptionId=b2a812004a8, topicName=MLL1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Fri Jun 30 10:44:00 CST 2017, time=2017-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780720, encodeId=a43b1e8072072, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Thu Jun 15 05:44:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870001, encodeId=4fe218e000143, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Apr 19 19:44:00 CST 2018, time=2018-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960260, encodeId=23dc196026064, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Sep 02 02:44:00 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424102, encodeId=96201424102dd, content=<a href='/topic/show?id=4ece524e593' target=_blank style='color:#2F92EE;'>#急性骨髓性白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52475, encryptionId=4ece524e593, topicName=急性骨髓性白血病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07ce3903085, createdName=zxxiang, createdTime=Thu Jun 15 14:44:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514409, encodeId=f21d15144090e, content=<a href='/topic/show?id=1ae010211143' target=_blank style='color:#2F92EE;'>#髓性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102111, encryptionId=1ae010211143, topicName=髓性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae8810654266, createdName=more is better!, createdTime=Thu Jun 15 14:44:00 CST 2017, time=2017-06-15, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2057544, encodeId=5f2e205e544d4, content=<a href='/topic/show?id=b2a812004a8' target=_blank style='color:#2F92EE;'>#MLL1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12004, encryptionId=b2a812004a8, topicName=MLL1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Fri Jun 30 10:44:00 CST 2017, time=2017-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780720, encodeId=a43b1e8072072, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Thu Jun 15 05:44:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870001, encodeId=4fe218e000143, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Apr 19 19:44:00 CST 2018, time=2018-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960260, encodeId=23dc196026064, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Sep 02 02:44:00 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424102, encodeId=96201424102dd, content=<a href='/topic/show?id=4ece524e593' target=_blank style='color:#2F92EE;'>#急性骨髓性白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52475, encryptionId=4ece524e593, topicName=急性骨髓性白血病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07ce3903085, createdName=zxxiang, createdTime=Thu Jun 15 14:44:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514409, encodeId=f21d15144090e, content=<a href='/topic/show?id=1ae010211143' target=_blank style='color:#2F92EE;'>#髓性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102111, encryptionId=1ae010211143, topicName=髓性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae8810654266, createdName=more is better!, createdTime=Thu Jun 15 14:44:00 CST 2017, time=2017-06-15, status=1, ipAttribution=)]
    2017-09-02 维他命
  5. [GetPortalCommentsPageByObjectIdResponse(id=2057544, encodeId=5f2e205e544d4, content=<a href='/topic/show?id=b2a812004a8' target=_blank style='color:#2F92EE;'>#MLL1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12004, encryptionId=b2a812004a8, topicName=MLL1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Fri Jun 30 10:44:00 CST 2017, time=2017-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780720, encodeId=a43b1e8072072, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Thu Jun 15 05:44:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870001, encodeId=4fe218e000143, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Apr 19 19:44:00 CST 2018, time=2018-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960260, encodeId=23dc196026064, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Sep 02 02:44:00 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424102, encodeId=96201424102dd, content=<a href='/topic/show?id=4ece524e593' target=_blank style='color:#2F92EE;'>#急性骨髓性白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52475, encryptionId=4ece524e593, topicName=急性骨髓性白血病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07ce3903085, createdName=zxxiang, createdTime=Thu Jun 15 14:44:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514409, encodeId=f21d15144090e, content=<a href='/topic/show?id=1ae010211143' target=_blank style='color:#2F92EE;'>#髓性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102111, encryptionId=1ae010211143, topicName=髓性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae8810654266, createdName=more is better!, createdTime=Thu Jun 15 14:44:00 CST 2017, time=2017-06-15, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2057544, encodeId=5f2e205e544d4, content=<a href='/topic/show?id=b2a812004a8' target=_blank style='color:#2F92EE;'>#MLL1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12004, encryptionId=b2a812004a8, topicName=MLL1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Fri Jun 30 10:44:00 CST 2017, time=2017-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780720, encodeId=a43b1e8072072, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Thu Jun 15 05:44:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870001, encodeId=4fe218e000143, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Apr 19 19:44:00 CST 2018, time=2018-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960260, encodeId=23dc196026064, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Sep 02 02:44:00 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424102, encodeId=96201424102dd, content=<a href='/topic/show?id=4ece524e593' target=_blank style='color:#2F92EE;'>#急性骨髓性白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52475, encryptionId=4ece524e593, topicName=急性骨髓性白血病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07ce3903085, createdName=zxxiang, createdTime=Thu Jun 15 14:44:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514409, encodeId=f21d15144090e, content=<a href='/topic/show?id=1ae010211143' target=_blank style='color:#2F92EE;'>#髓性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102111, encryptionId=1ae010211143, topicName=髓性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae8810654266, createdName=more is better!, createdTime=Thu Jun 15 14:44:00 CST 2017, time=2017-06-15, status=1, ipAttribution=)]

相关资讯

盘点:近期有关急性骨髓性白血病(AML)相关进展

AML是一种骨髓性白细胞(而非淋巴性白细胞)异常增殖的血癌。其特点是骨髓内异常细胞的快速增殖而影响了正常血细胞的产生。AML是成年人最常见的急性白血病。【1】NEJM:急性骨髓性白血病至少可分11类美国《新英格兰医学杂志》8日刊登一项大型研究显示,急性骨髓性白血病不是单一病症,从基因角度可视为至少11类疾病。科学家认为,这是在恶性血癌精准医疗研究领域取得的“里程碑式”进展。研究负责人之一、英国

Blood: 骨髓内血癌细胞调节脂肪细胞代谢创造出一个利于癌细胞生长的微环境

骨髓内血癌细胞调节脂肪细胞代谢创造出一个利于癌细胞生长的微环境

NEJM:急性骨髓性白血病至少可分11类

美国《新英格兰医学杂志》8日刊登一项大型研究显示,急性骨髓性白血病不是单一病症,从基因角度可视为至少11类疾病。科学家认为,这是在恶性血癌精准医疗研究领域取得的“里程碑式”进展。研究负责人之一、英国桑格研究所的彼得·坎贝尔在一份声明中解释说:“在显微镜下看,两个人也许得的是同样的白血病;但从基因层面看,他们的白血病有很大不同。这些基因区别能在很大程度上解释为什么同一种疗法能治好有些患者,却治不好其

Baidu
map
Baidu
map
Baidu
map